section is usually the treatment of choice. It can rapidly decompress the mass effect of MBTs and relieve the neurological deterioration caused by peritumoral edema.
There is an ongoing debate about the optimal management of MBTs. Stereotactic radiosurgery has recently become more accepted as an alternative treatment because many patients with brain metastases are not optimal candidates for resection and some refuse an open procedure. In the last few decades, satisfactory radiosurgical outcomes in treating small to moderate-size MBTs have been reported after long-term follow-up. 15 Radiosurgery is used typically to treat brain metastases that are 3 cm or smaller in maximum diameter. Nevertheless, in the RTOG 9508 study, the use of radiosurgery was permitted for one tumor that was up to 4 cm in diameter. 1 To date, there have been few reports discussing the specific outcome of treatment of large MBTs. 6, 20 For this retrospective report, we reviewed the cases involving MBTs larger than 3 cm in diameter treated with GKS at the University of Virginia. We evaluated the efficacy and safety of single-session GKS for treating these large brain metastases. Several clinical parameters were scrutinized as potential predictors of successful treatment of large MBTs.
Methods

Patient Population
We defined a large brain metastasis as one having a diameter of greater than 3 cm in at least one dimension. From October 2000 to December 2012, 109 patients with 119 large MBTs were treated with GKS at the University of Virginia. Follow-up MRI studies, which were performed within 2-3 months after the GKS treatment, were available for all 109 patients. The study was approved by the institutional review board of the University of Virginia.
The median age of these patients was 60.5 years, and the group included 51 males and 58 females. The median tumor volume was 16.8 cm 3 (range 6.0-74.8 cm 3 ). Most patients (68.8%%) had multiple intracranial lesions, and 31.2% of patients had metastasis to other organs. The most common tumor of origin was NSCLC (29.4% of cases), followed by breast cancer (22.9%) and melanoma (21.1%). Of note, those patients included in the current series with SCLC had prior WBRT and demonstrated new or progressive tumors that were targeted with GKS. Prior microsurgical resection had been performed for 36 patients (33.0%), and 43 patients (39.4%) had been treated with WBRT before GKS. To relieve their neurological symptoms, 100 patients (91.7%) were being treated with steroid medication prior to GKS. For patients not receiving steroid therapy prior to GKS, one dose of steroid medication was administered at the time of radiosurgery. Preoperative MR images were carefully reviewed to assess tumor volume, tumor components, and the presence of peritumoral edema on T2-weighted or FLAIR MRI sequences (Table 1) .
Gamma Knife Surgery
Radiosurgery was performed using the Leksell Gamma Unit Model C before 2007, and Perfexion (Elekta AB) after 2007. Treatment planning was done using GammaPlan software (Elekta AB). The gross tumor volume was defined using pre-and post-contrast MRI sequences. The planned treatment volume was designed to mirror the gross tumor volume without any appreciable expansion. Multi-isocenter dose planning was used. The radiosurgical margin dose (median 18.0 Gy, range 16.0-26.0 Gy) was prescribed at an isodose level of 30%-70% (median 50%). The median maximum dose to the target tumor volume was 40.0 Gy (range 17.1-66.7 Gy) ( Table 2) . 
Follow-Up Imaging and Clinical Evaluation
After GKS, all patients had regular follow-up by MRI and clinical evaluation at 2-to 3-month intervals. The performance status was scored using the Karnofsky Performance Status (KPS) scale. Changes in tumor volume and characteristics were assessed on follow-up neuroimaging. Tumor response was evaluated on contrast-enhanced T1-weighted images, and edema volume was defined as the peritumoral increased signal detected on T2-weighted images. The tumor and brain edema responses to GKS on MRI studies were classified into 3 categories: 1) decreased, if the area of tumor volume (on contrast-enhanced T1-weighted images) plus the peritumoral area of signal hyperintensity on T2-weighted images had lessened by more than 10% of its original size at the time of GKS; 2) a stable volume, if the area was within 10% of the original size; and 3) increased, if the volume had increased by more than 10%.
Tumor and edema volumes were calculated from the sum of the areas contoured on each slice, multiplied by the slice thickness. Based upon our previous work, the trapezoidal rule formula demonstrates that with accurate delineation on at least 5 slices, calculated volume would have an expected error rate of 10% or less. 17 Therefore, this kind of measurement generally has an uncertainty of 10% for tomographic imaging used for radiosurgery of a structural target such as a tumor. 17 After GKS, the patients' symptoms, signs, steroid dosage, and any other treatment were documented. Patients were followed up every 3 months afterward.
Statistical Analysis
Analysis was performed with traditional bivariate tests: independent t-test, one-way analysis of variance, and Pearson correlation. Categorical variables, such as sex, were analyzed by the chi-square test. Nevertheless, nonparametric tests (Mann-Whitney U test, Kruskal-Wallis H test, and Spearman's rank correlation) were used when the conditions required by classic tests were not obviously met. Significant variables and interaction expansion covariates (we chose p = 0.15 as the cutoff point) were further assessed in both Cox and logistic multivariable analyses as deemed relevant. A p value of 0.05 or less was considered statistically significant. A Kaplan-Meier plot was used to assess overall survival, and a log-rank test was performed for survival comparison. All statistical analyses in this study were performed using commercially available statistical software (IBM SPSS Statistics 20.0).
Results
Tumor Response and Brain Edema Response After GKS
The median duration of post-GKS imaging followup for patients with large MBTs in this series was 6.3 months. In the first 3 months of follow-up, 77 MBTs showed regression, 24 MBTs were stable, and 18 MBTs were in progression. On the other hand, perifocal edema of 79 MBTs regressed, that of 21 MBTs was stable, and that of the other 19 was in progression. Conclusively, 84.9% of the MBTs had regressed or remained stable, and 84.0% of the MBTs had perifocal brain edema volume regression or were in stable condition (Table 3) .
For the patients who survived longer than 6 months (76 patients with 77 MBTs), we further evaluated their tumor response and brain edema at 3-month intervals. In the most recent imaging studies obtained in these patients, 88.3% of the MBTs (68 of 77) had regressed or remained stable in size, and 89.6% of the MBTs (69 of 77) were found to have a reduced or stable volume of perifocal brain edema.
In addition, the patients with previous WBRT had worse tumor response and brain edema response. The detailed clinical data are listed in Table 3 . Figure 1 illustrates 2 cases in which there was satisfactory tumor regression 3 months after radiosurgery.
Neurological Outcomes
The median duration of clinical follow-up after GKS was 7.4 months ( In the current study, there was no statistically significant relationship between any of the following factors and tumor control or brain edema control: age at the time of GKS, sex, number of intracranial metastatic lesions, extracranial metastasis, initial tumor volume, KPS score, prescribed radiation dose (including maximum dose and margin dose), previous radiosurgery (for other lesions), previous resection, and previous chemotherapy ( Table 4) . The absence of previous WBRT and the presence of small cell lung cancer (SCLC) histology were favorable factors for tumor control and improvement in brain edema (p < 0.05 for each).
Presence of only a single MBT, higher pre-GKS KPS score, absence of previous radiosurgery or WBRT, and presence of SCLC histology were all independently associated with an increased likelihood of reduced steroid dosage within 2-3 months following GKS (p < 0.05 for each). In terms of survival in this cohort of patients with large brain metastases, the only prognostic factor was the pre-GKS KPS score. A better KPS score was significantly related to improved overall survival after GKS (p = 0.024) (Fig. 2) .
Complications
Radiation necrosis of brain parenchyma after GKS was not seen in this series. However, one patient with NSCLC had a stable tumor but exacerbation of his brain edema, which we would attribute to GKS. Due to poor overall condition as well as systemic disease progression, the patient did not undergo a craniotomy and tumor resection, but he was treated with a prolonged course of steroid therapy, which helped to lessen the symptoms related to his edema. The patient eventually died slightly more than 6 months after GKS without signs of necrosis on his last brain MRI study. Her KPS score at the time of treatment was 80. Two months after GKS, the tumor volume and edema volume were reduced significantly. The patient survived 14.5 months following GKS. B: Axial T1-weighted Gd-enhanced (left) and T2-weighted (right) MR images obtained in a 60-year-old woman with breast cancer and MBTs, including 1 large brain metastasis. Her clinical symptoms included headache, paresthesias, and an unsteady gait. She had no prior WBRT or resection. Her KPS score was 90 at the time of GKS. Three months after GKS, the tumor volume was stable, and the brain edema had dramatically improved. The patient was still alive 7 months after GKS. M = months.
Discussion
Management of Large Brain Metastases
Although the development of MBTs was formerly considered a terminal event, patients can now survive longer as a result of improved local and systemic therapies. 5 Standard treatment for patients with MBTs includes resection, WBRT, single-or multisession radiosurgery, or a combination of these modalities depending on the clinical situation.
Stereotactic radiosurgery works well in treating patients with oligo-metastatic disease and small to moderate-size MBTs. It offers favorable local tumor control and often early volume reduction, depending on the particular type of carcinoma. 2, 3, 11, 16 After radiosurgery, approximately 1.2% of patients with small to moderate-size MBTs undergo resection due to radiation necrosis and tumor progression. 10 Very few studies have specifically evaluated the outcome of radiosurgical treatment of large MBTs. The main concern was that large MBTs usually cause a mass effect and brain edema, and for this reason their size has historically been considered a relative contraindication for GKS. In this situation, neurosurgeons have generally preferred resection. However, not all patients with large MBTs are willing or able to undergo such surgery. Moreover, many neurological symptoms and signs can be temporarily relieved by steroid therapy while the effects of a definitive treatment are realized.
In our case series, most patients with large MBTs who were treated with stereotactic radiosurgery obtained reasonable results. The majority of patients with large brain metastases exhibited significant tumor volume reduction and brain edema relief simultaneously during the initial 2-3 months following GKS. Worsening local peritumoral edema as a result of tumor progression or radiation-induced changes occurs more frequently in patients with large brain metastases than in those with moderate to small ones. In our experience, worsening edema after GKS has occurred in 16.0% of large MBTs. In such cases, resection or WBRT remain treatment options. However, our experience suggests that many patients with large brain metastases and symptoms that are reasonably well controlled by steroid therapy can be treated with GKS and avoid a resection.
Other studies have reported results following radiosurgery for large brain metastases. At 2 months postradiosurgery, Yang and colleagues 20 noted that 74% of patients had improved symptoms, and 54% had tapered or were no longer using steroids. In the same series, the local tumor control rate was 91.4%, with 41% of tumors exhibiting a volume reduction of more than 50% at the first imaging follow-up, and the brain edema control rate was 81.4%. In another study, Han and colleagues 7 noted that 85% of patients with large brain metastases showed functional improvement or maintained their independent function status 1-4 months after radiosurgery. These reports and our current study suggest that radiosurgery can be used to achieve local control and reduce peritumoral edema in selected patients with brain metastasis over 3 cm in diameter ( Table 5) .
Prediction of Local Tumor Control for Large Brain Metastases Treated With Radiosurgery
The goal in treating MBTs is not cure of widely metastatic cancer; rather, treatment is undertaken in order to keep the patient from succumbing to intracranial disease. Once the local tumor is controlled, patients will have opportunities to be treated for the primary cancers and other extracranial sites of metastatic disease. From our analysis, lack of prior WBRT and the presence of SCLC histology are the most favorable factors for local tumor control of a large brain metastasis following GKS. The radiosensitivity of SCLC makes tumor control after GKS more likely. Both Yang et al. 20 and Han et al. 6, 7 found that patients without prior WBRT had a higher likelihood of tumor volume stability or reduction than those who had been treated with WBRT. Others factors, including age, sex, numbers of intracranial metastases, extracranial metastasis, and radiation dose, were not related to local tumor control of large brain metastasis after GKS (Table 5) .
Patients with large MBTs usually have shorter duration of survival. 6, 7, 20 In the present study, the median survival, based on Kaplan-Meier analysis, was 8.3 months. The only prognostic factor was the pre-GKS KPS score, with those patients who had a better KPS score exhibiting longer survival. In the studies by Han and colleagues, 6, 7 prolonged survival of patients in these reports was related to the control of primary disease, marginal dose > 11 Gy, and tumor volume < 26 cm 2 (Table 5 ). KPS and control of systemic disease are often related factors and play a significant role in predicting survival-not just in patients with large brain metastasis, but in patients with smaller ones, too.
GKS and Peritumoral Edema Associated With Large Brain Metastases
In our study, tumor volume reduction, and a significant reduction in edema volume occurred in 63.0% of tumors (75 of 119) simultaneously within 3 months of GKS. The extent of edema relief, whether mild or significant, was substantially related to the underlying tumor response following GKS. The patients' neurological symptoms were usually improved and corresponded to the findings of follow-up MRI studies. From the pathophysiological perspective, MBT-induced brain edema is due to vasogenic causes, not cytotoxic ones. Available evidence points to a group of proteinaceous vascular permeability factors 18 (for example, VEGF) associated with increased regional capillary permeability in electron micrograph and protein-bound tracer studies. 8, 13 Once radiosurgery interrupts the vicious cycle of vasogenic edema, symptomatic relief of brain edema can be expected. The current study, however, shows that worsening edema following GKS appears to be more likely with treatment of a large brain metastasis than with treatment of smaller ones. Worsening edema associated with adverse radiosurgical changes and/or tumor progression can be treated with resection, pentoxifylline, vitamin E, or WBRT, along with concomitant steroid therapy.
What Size is "Too Big"?
There is certainly an upper limit at which the risks will exceed the benefits of radiosurgery for brain metastasis. This upper limit is almost certainly going to be defined by a volume rather than a linear dimension, although the neurosurgical literature is filled with linear dimension cutoffs for radiosurgery, such as the traditional 3-cm dogma. The brain metastasis size limit is likely lower for single-session radiosurgery than for multisession radiosurgery. All patients in the current study were treated with single-session GKS. The study was not designed to define the limit, and any upper limit derived from the current data would not be well supported. However, other studies do point to an upper limit. For example, Higuchi et al. treated brain metastases up to 25 cm 3 in volume using 3-session GKS. 9 Using hypofractionated stereotactic radiotherapy, Jiang et al. treated metastases up to 5.5 cm in diameter. 12 Nishizaki et al. used multisession CyberKnife radiosurgery to treat brain metastases up to 53.2 cm 3 in volume.
14 Future studies will have to better define the upper limit in volume for single-and multisession radiosurgery to a brain metastasis.
Study Limitation
The current study is a retrospective study. Inherent to this study design, there exist patient selection and treatment biases reflective of the treating clinicians and the institution in which we practice. For example, the selection factors in determining the treatment cohort (KPS score > 70) probably meant that the lesions were less likely to be in an eloquent brain location. Also, the decision to employ preradiosurgical WBRT was not always arrived at in a uniform fashion, as this decision was made at times by community physicians. This nonuniformity of WBRT in the preradiosurgical setting for some patients could have introduced a bias into the study.
Conclusions
Although a brain metastasis with a diameter larger than 3 cm has been a relative contraindication for radiosurgery, GKS does appear to offer a reasonable benefit for those patients with large brain metastases who are not suitable candidates for microsurgery or for those in whom 
